Watch the interview with Paul Hargreaves, in English, below.
In March, Spago Nanomedical announced that an independent monitoring committee had recommended a dose escalation in the company's ongoing Phase I/IIa study with candidate 177Lu-SN201. This is an important step in the study, which Paul Hargreaves, CDO at Spago Nanomedical, explains more about in an interview with BioStock.